2,626 Shares in Cencora, Inc. $COR Purchased by Rockland Trust Co.

Rockland Trust Co. bought a new position in shares of Cencora, Inc. (NYSE:COR) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,626 shares of the company’s stock, valued at approximately $821,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Atlantic Edge Private Wealth Management LLC grew its holdings in shares of Cencora by 70.0% in the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after acquiring an additional 35 shares during the period. Vermillion & White Wealth Management Group LLC raised its holdings in Cencora by 69.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after purchasing an additional 43 shares during the last quarter. Cloud Capital Management LLC purchased a new stake in Cencora during the third quarter worth $31,000. Westside Investment Management Inc. boosted its position in Cencora by 200.0% during the third quarter. Westside Investment Management Inc. now owns 105 shares of the company’s stock worth $33,000 after purchasing an additional 70 shares in the last quarter. Finally, Copia Wealth Management grew its holdings in Cencora by 505.0% in the third quarter. Copia Wealth Management now owns 121 shares of the company’s stock valued at $38,000 after purchasing an additional 101 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,677 shares of the firm’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the sale, the executive vice president directly owned 18,796 shares of the company’s stock, valued at approximately $6,484,620. This trade represents a 8.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total value of $1,807,704.08. Following the completion of the sale, the chief executive officer owned 66,726 shares of the company’s stock, valued at $23,669,713.98. This trade represents a 7.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 20,316 shares of company stock worth $7,151,265 over the last quarter. 0.38% of the stock is currently owned by insiders.

More Cencora News

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: JPMorgan raised its price target to $419 and kept an “overweight” rating, implying roughly mid‑teens upside from current levels — a notable analyst endorsement that can support the stock. Benzinga
• Positive Sentiment: Cencora selected a new $106M distribution site in Greater Cincinnati (Hillwood), expanding logistics capacity that should support revenue growth and margin improvement over time. Cincinnati Business Journal
• Positive Sentiment: Pharma distribution wins: SQ Innovation’s Lasix ONYU gained access to major U.S. distributors, including Cencora, which could provide incremental product revenue and market‑access momentum. Yahoo Finance
• Neutral Sentiment: Cencora updated its segment reporting following a strategic business review; this improves disclosure but may temporarily complicate comparability to prior periods. TipRanks
• Neutral Sentiment: The company’s ~$2B physician‑group buyout is being framed as a strategic move into provider services; it supports growth strategy but carries integration risk and financing implications. Becker’s ASC
• Neutral Sentiment: Non‑financial/PR items such as executive recognition and analyst‑target aggregation pages surfaced; these are low impact on near‑term valuation. Yahoo Finance — Corporate Purpose
• Negative Sentiment: Cencora priced $3.0 billion of senior notes across five tranches (2029–2056) with coupons from 3.95% to 5.65% — a large debt raise that increases gross leverage and future interest expense; given the company’s already elevated debt metrics, the bond sale is the clearest near‑term headwind for the stock. Business Wire Yahoo Finance

Analysts Set New Price Targets

COR has been the subject of several research reports. TD Cowen lifted their price target on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Mizuho raised their target price on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. UBS Group lifted their target price on shares of Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Wells Fargo & Company increased their price target on shares of Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a research report on Tuesday. Finally, Jefferies Financial Group raised shares of Cencora from an “underperform” rating to a “buy” rating in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $396.92.

Cencora Stock Performance

Shares of NYSE COR opened at $360.00 on Wednesday. The company has a market cap of $69.84 billion, a PE ratio of 43.27, a price-to-earnings-growth ratio of 1.67 and a beta of 0.68. Cencora, Inc. has a 12 month low of $237.71 and a 12 month high of $377.54. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51. The company has a 50-day simple moving average of $346.17 and a 200-day simple moving average of $327.39.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The business had revenue of $85.93 billion for the quarter, compared to the consensus estimate of $86.12 billion. During the same quarter in the prior year, the firm posted $3.73 earnings per share. The company’s quarterly revenue was up 5.5% compared to the same quarter last year. On average, equities analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Stockholders of record on Friday, February 13th will be issued a dividend of $0.60 per share. The ex-dividend date is Friday, February 13th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s dividend payout ratio (DPR) is 28.85%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.